SABS
- SAB Biotherapeutics, Inc.
()
Overview
Company Summary
SAB Biotherapeutics, Inc. (SAB) is a biopharmaceutical company that specializes in developing and producing human polyclonal antibodies. Unlike traditional antibody-based therapies, SAB utilizes its unique platform to generate fully human antibodies in transgenic cattle.
SAB's technology relies on the natural immune response of cattle to produce and release large quantities of fully human polyclonal antibodies against specific antigens. These antibodies are similar to those found in the human immune system, making them safe and effective for therapeutic use.
The company's innovative approach involves introducing specific genes into cattle embryos, which result in the animals producing human antibodies once they reach adulthood. SAB collects blood samples from the transgenic cattle and extracts the human antibodies present in their plasma.
SAB's technology offers several advantages over other antibody-based therapies. Since the antibodies are fully human, they have a lower risk of triggering an immune response in patients compared to therapies using antibodies derived from other sources. Moreover, the scalable and efficient production process allows for the rapid generation of antibodies against various targets.
The applications of SAB's technologies are widespread, with potential uses in treating infectious diseases, autoimmune disorders, and even cancer. By developing a robust pipeline of therapeutic candidates, SAB aims to advance the field of antibody-based therapies and make a significant impact on human health.
In summary, SAB Biotherapeutics, Inc. specializes in the development and production of fully human polyclonal antibodies using transgenic cattle. Their unique platform has the potential to revolutionize antibody-based therapies and address various medical conditions.